IBT Reference Laboratory Appoints Dr. F. John Mills to its Board of Directors.
ProGene Biomedical, Inc. (d/b/a IBT Reference Laboratory), a national clinical and pharmaceutical services laboratory, announced that Dr. F. John Mills has joined its Board of Directors.
Lenexa, KS, June 2, 2005. ProGene Biomedical, Inc. (d/b/a IBT Reference Laboratory), a national clinical and pharmaceutical services laboratory, announced that Dr. F. John Mills has joined its Board of Directors. "Dr. Mills brings over 20 years of senior executive experience in drug discovery and the pharmaceutical services industry to our Board. His unique background will be invaluable as IBT seeks to build a premier company in the specialty pharmaceutical services sector," according to John F. Halsey, PhD, the President and Chief Executive Officer of ProGene Biomedical, Inc.
Dr. Mills, who received both medical and doctoral degrees in the United Kingdom, was an executive at Janssen Pharmaceutical from 1983 to 1991, serving as UK Medical Director and Regional Medical Director for Asia. From 1992 to 2002, Dr. Mills held various senior executive positions with Covance, Inc., including General Manager of European Clinical Services, Global General Manager of Central Laboratory Services and President of Clinical Support Services. Dr. Mills is the co-founder and Chief Executive Officer of BioStorage Technologies, Inc., a leading provider of biological sample repository services to pharmaceutical, biotechnology and other life sciences companies (www.bst-indy.com).
"John knows what it takes to build a well-respected, laboratory services business from his years at Covance," commented David Parker, IBT's Chairman and a partner at Ampersand Ventures. "His input and guidance will be very important as the Company looks to capitalize on growing demand for its assay development and diagnostic testing services from pharmaceutical sponsors to support their clinical trials."
About IBT Reference Laboratory:
Founded in 1983, IBT Reference Lab is a national research and specialty clinical lab that provides a range of esoteric tests in the areas of clinical immunology, allergy and molecular biology. In addition to all of the major national clinical laboratories, the Company provides its unique biomarker and immunotoxicology testing services to pharmaceutical and biotechnology companies and academic institutions (www.ibtreflab.com).
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
